Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors

von Pal, Sumanta Kumar, Figlin, Robert A.
Veröffentlicht 2010

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

von Pal, Sumanta Kumar, Figlin, Robert A.
Veröffentlicht 2011

A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy

von Banerjee, Natasha, Sachdev, Esha, Figlin, Robert A
Veröffentlicht in Cureus (2016)

Deciphering the anticancer mechanisms of sunitinib

von Pal, Sumanta Kumar, Figlin, Robert A, Yu, Hua
Veröffentlicht 2010

Targeted Therapies for Non-Small Lung Cancer: An Evolving Landscape

von Pal, Sumanta Kumar, Figlin, Robert A., Reckamp, Karen
Veröffentlicht 2010

A New Age for Vaccine Therapy in Renal Cell Carcinoma

von Pal, Sumanta K., Hu, Adriana, Figlin, Robert A.
Veröffentlicht 2013

Renal cell carcinoma: An update for the practicing urologist

von Pal, Sumanta K., Bergerot, Paulo, Figlin, Robert A.
Veröffentlicht in Asian J Urol (2015)

Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer

von Reed, Jarred P., Devkota, Suzanne, Figlin, Robert A.
Veröffentlicht in Ann Transl Med (2019)

Renal cell carcinoma molecular targets and clinical applications, second edition /

von Bukowski, Ronald M., Figlin, Robert A., Motzer, Robert J.
Veröffentlicht 2009

Renal cell carcinoma translational biology, personalized medicine, and novel therapeutic targets /

von Figlin, Robert A., Rathmell, W. Kimryn., Rini, Brian I.
Veröffentlicht 2012

Chemokines as therapeutic targets in renal cell carcinoma

von Reckamp, Karen L, Strieter, Robert M, Figlin, Robert A
Veröffentlicht 2008

Tivozanib: Current status and future directions in the treatment of solid tumors

von Pal, Sumanta K., Bergerot, Paulo G., Figlin, Robert A.
Veröffentlicht 2012

Surveillance Strategies for Renal Cell Carcinoma Patients Following Nephrectomy

von Chin, Arnold I, Lam, John S, Figlin, Robert A, Belldegrun, Arie S
Veröffentlicht 2006

Akt inhibitors in clinical development for the treatment of cancer

von Kumar Pal, Sumanta, Reckamp, Karen, Yu, Hua, Figlin, Robert A.
Veröffentlicht 2010

Breaking through a plateau in renal cell carcinoma therapeutics: Development and incorporation of biomarkers

von Pal, Sumanta Kumar, Kortylewski, Marcin, Yu, Hua, Figlin, Robert A.
Veröffentlicht 2010

Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma

von Motzer, Robert J., Escudier, Bernard, Gannon, Andrew, Figlin, Robert A.
Veröffentlicht in Oncologist (2016)

Systemic Therapies for Metastatic Renal Cell Carcinoma in Older Adults

von Pal, Sumanta K., Vanderwalde, Ari, Hurria, Arti, Figlin, Robert A.
Veröffentlicht in Drugs Aging (2011)

STAT3: A Target to Enhance Antitumor Immune Response

von Lee, Heehyoung, Pal, Sumanta Kumar, Reckamp, Karen, Figlin, Robert A., Yu, Hua
Veröffentlicht 2011

A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models

von Zhang, Hao, Berel, Dror, Wang, Yanping, Li, Ping, Bhowmick, Neil A., Figlin, Robert A., Kim, Hyung L.
Veröffentlicht 2013

CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer

von Reckamp, Karen L, Figlin, Robert A, Burdick, Marie D, Dubinett, Steven M, Elashoff, Robert M, Strieter, Robert M
Veröffentlicht 2009